Oxaceprol - A randomised, placebo-controlled clinical study in osteoarthritis with a non-conventional non-steroidal anti-inflammatory drug

Clinical and Experimental Rheumatology

Volumn 25, Issue 1, 2007, Pages 29-34

  Krüger, Klaus ^a   Klasser, Manfred ^b   Mössinger, Jürgen ^c   Becker, Uta ^d  

^a Praxiszentrum St Bonifazius   (Germany)

^b Gwd consult ^*  (Germany)

^c Chephasaar GmbH   (Germany)

^d Medical Development and Services   (Germany)

Author keywords

Drug safety; Efficacy; Hip; Knee; Non Steroidal anti inflammatory agents; Osteoarthritis; Oxcaperol; Pain; Placebo

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; OXACEPROL; PARACETAMOL; PLACEBO;

ADULT; AGED; APPETITE; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC PAIN; ERUCTATION; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLATULENCE; HIP OSTEOARTHRITIS; HIP RADIOGRAPHY; HUMAN; INFECTION; JOINT EXAMINATION; JOINT FUNCTION; JOINT LIMITATION; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; OSTEOARTHRITIS; PAIN ASSESSMENT; PHYSIOTHERAPY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STUDENT T TEST; URIC ACID BLOOD LEVEL; VISUAL ANALOG SCALE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYPROLINE; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33947583913     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fachinformationsverzeichnis Deutschland AHP 200®, BPI Service GmbH CD-version, issue 2005/4.
2. e édition. Jonctum® 200 mg gélule, oxaceprol: 1054.
3. PARNHAM MJ: Antirheumatic agents and leukocyte recruitement. Biochem Pharmacol 1999; 58: 209-15.
4. IONAC M, PARNHAM MJ, PLAUCHITHIU M, BRUNE K: Oxaceprol, an atypical inhibitor of inflammation and joint damage. Pharmacol Res 1996; 33: 367-73.
5. BAUER HW, KLASSER M, von HANSTEIN KL et al.: Oxaceprol is as effective as diclofenac in the therapy of osteoarthritis of the knee and hip. Clin Rheumatol 1999; 18: 4-9.
6. HERRMANN G, STEEGER D, KLASSER M et al.: Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac. Clin Rheumatol 2000; 19: 99-104.
7. ALTMAN R, BRANDT K, HOCHBERG M, MOSKOWITZ R: Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage 1996; 4: 217-43.
8. Group for the Respect of Ethics and Excellence in Science (GREES): osteoarthritis section. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis 1996; 55: 552-7.
9. The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit. Committee for Prorietary Medicinal Products (CPMP): Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis. CPMP/EWP/784/97: 1-6.
10. LEQUESNE MG, MERY C, SAMSON M, GERARD P: Indexes of severity for osteoarthritis of the hip and knee. Scand J Rheumatology 1987 (Suppl. 65): 85-9.
11. FELDMAN S, BERGAL S, NORES JM et al.: Traitement par la N-acetyl-hydroxyproline des arthropathies dégénératives. Analyse et synthèse de 7 essais cliniques. Rhumatologie 1994; 46: 281-6.
12. BELLAMY N: The WOMAC knee and hip osteoarthritis indices: development, validation, globalization and influence on the development of the AUSCAN hand osteoarthritis indices. Clin Exp Rheumatol 2005; 23 (Suppl. 39): 148-53.
13. DOUGADOS M, LeCLAIRE P, van der HEIJDE D, BLOCH DA, BELLAMY N, ALTMAN RD: A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative. Osteo Arthritis and Cartilage 2000; 8: 395-403.
14. KELLY AM: The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J 2001; 18: 205-7.
15. FALGARONE G, ZERKAK D, BAUER C, MESSOW M, DOUGADOS M: How to define a Minimal Clinically Individual State (MCIS) with pain VAS in daily practice for patients suffering from musculoskeletal disorders. Clin Exp Rheumatol 2005; 23: 235-8.
16. KIVITZ A, EISEN G, ZHAO WW, BEVIRT T, RECKER DP: Randomized placebo-controlled trial comparing efficacy and safety of Valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002; 51: 1-9.
17. WILLIAMS G, HUBBARD RC, YU SS, ZHAO W, GEIS GS: Comparison of once-daily and twice-daily administration of Celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001; 23: 213-27.
18. HARRIS AG, SCHROPP A, MEßMER K: Oxaceprol reduziert die Leukozyten-Adhärenz und - Extravasation and erhält die Perfusion des Gewebes nach Ischämie/Reperfusion (I/R) aufrecht. [Oxaceprol reduces leukocyte adherence and extravasation and maintains tissue perfusion after ischemia/reperfusion (I/R).] In: HERFARTH C (Ed.): Langenbecks Arch Chir I (Forumband 1998): 447-51.
19. VEIHELMAN A, HOFBAUER A, REFIOR HJ, MESSMER K: Oxaceprol, an atypical inhibitor of inflammation, reduces leukocyte adherence in mouse antigen-induced arthritis. Acta Orthop Scand 2001; 72: 293-8.
20. HALLMANN R, ZHOU X, BRUNE K, ZIMMERMANN U: Blockade der Leukocytenadhäsion an Gefäßendothel. Z Rheumatol 1996; 55 (Suppl.1): 3-4.